Latest News and Press Releases
Want to stay updated on the latest news?
-
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
-- Plazomicin granted Breakthrough Therapy designation -- -- C-Scape Phase 1 study underway to evaluate orally-administered antibacterial candidate for infections due to ESBL-producing...
-
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
-
-- CARB-X funding highlights Achaogen’s innovative LpxC program and urgent need for gram-negative antibiotics -- -- Awarded $3.2 million over 12 months, and potentially up to a total award of $11.4...
-
SOUTH SAN FRANCISCO, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
SOUTH SAN FRANCISCO, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
SOUTH SAN FRANCISCO, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
-
-- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrated potent activity of plazomicin against contemporary...
-
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing...
-
SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...